万邦医药
(301520)
| 流通市值：8.43亿 | | | 总市值：25.47亿 |
| 流通股本：2207.34万 | | | 总股本：6666.67万 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 173,284,439.23 | 175,323,414.01 | 238,745,336.87 | 253,496,974.51 |
| 结算备付金 | - | - | - | 0 |
| 拆出资金 | - | - | - | 0 |
| 衍生金融资产 | - | - | - | 0 |
| 应收票据及应收账款 | 82,876,652.14 | 66,725,035.15 | 67,818,992.5 | 59,797,972.34 |
| 其中：应收票据 | 13,245,445.63 | 9,390,935.98 | 7,227,544.57 | 6,775,206.8 |
| 应收账款 | 69,631,206.51 | 57,334,099.17 | 60,591,447.93 | 53,022,765.54 |
| 应收款项融资 | - | - | - | 0 |
| 预付款项 | 10,410,522.95 | 10,847,125.57 | 9,202,824.42 | 8,613,679.05 |
| 应收保费 | - | - | - | 0 |
| 应收分保账款 | - | - | - | 0 |
| 应收分保合同准备金 | - | - | - | 0 |
| 其他应收款合计 | 4,586,966.87 | 3,789,828.58 | 3,581,647.96 | 3,236,287.38 |
| 其中:应收利息 | - | - | - | 0 |
| 应收股利 | - | - | - | 0 |
| 买入返售金融资产 | - | - | - | 0 |
| 存货 | 840,279.68 | 1,022,292.34 | 584,161.84 | 666,513.2 |
| 合同资产 | 94,397,398.53 | 93,246,661.61 | 85,050,408.73 | 75,293,467.41 |
| 一年内到期的非流动资产 | - | - | 0 | 0 |
| 其他流动资产 | 60,006,274.56 | 59,088,852.9 | 61,768,006.94 | 58,265,550.75 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,394,558,447.3 | 1,373,171,254.81 | 1,376,735,121.42 | 1,362,183,442.36 |
| 非流动资产: | | | | |
| 发放委托贷款及垫款 | - | - | - | 0 |
| 债权投资 | - | - | - | 0 |
| 其他债权投资 | - | - | - | 0 |
| 长期应收款 | - | - | - | 0 |
| 长期股权投资 | - | - | - | 0 |
| 其他权益工具投资 | - | - | - | 0 |
| 其他非流动金融资产 | - | - | - | 0 |
| 投资性房地产 | 7,082,917.82 | 7,180,781.03 | 7,278,644.24 | 7,376,507.45 |
| 固定资产 | 177,272,635.61 | 167,267,355.24 | 156,702,424.56 | 150,006,036.2 |
| 在建工程 | - | - | - | 0 |
| 生产性生物资产 | - | - | - | 0 |
| 油气资产 | - | - | - | 0 |
| 使用权资产 | - | - | - | 0 |
| 无形资产 | 15,237,571.89 | 11,438,770.88 | 11,719,960.85 | 12,001,150.82 |
| 开发支出 | - | 4,282,396.15 | 4,271,502.4 | 4,130,828.46 |
| 商誉 | - | - | 0 | 0 |
| 长期待摊费用 | 4,254,534.02 | 4,542,554.69 | 5,211,086.08 | 5,452,374.71 |
| 递延所得税资产 | 200,290.53 | 269,948.15 | 165,864.21 | 113,037.38 |
| 其他非流动资产 | 1,237,147.79 | 2,991,812.68 | 6,715,392.55 | 3,326,011.65 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 205,285,097.66 | 197,973,618.82 | 192,064,874.89 | 182,405,946.67 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,599,843,544.96 | 1,571,144,873.63 | 1,568,799,996.31 | 1,544,589,389.03 |
| 流动负债: | | | | |
| 短期借款 | - | - | - | 0 |
| 向中央银行借款 | - | - | - | 0 |
| 吸收存款及同业存放 | - | - | - | 0 |
| 拆入资金 | - | - | - | 0 |
| 交易性金融负债 | - | - | - | 0 |
| 衍生金融负债 | - | - | - | 0 |
| 应付票据及应付账款 | 38,617,305.36 | 32,497,872.91 | 28,148,776.72 | 27,021,753.8 |
| 其中：应付票据 | - | - | - | 0 |
| 应付账款 | 38,617,305.36 | 32,497,872.91 | 28,148,776.72 | 27,021,753.8 |
| 预收款项 | - | - | 0 | 0 |
| 合同负债 | 15,588,512.09 | 18,072,085.26 | 18,470,102.35 | 20,652,917.2 |
| 卖出回购金融资产款 | - | - | - | 0 |
| 应付手续费及佣金 | - | - | - | 0 |
| 应付职工薪酬 | 14,356,500.12 | 10,228,303.99 | 7,235,094.98 | 14,699,270.56 |
| 应交税费 | 1,292,481.64 | 3,026,754.06 | 856,332.86 | 1,363,456.01 |
| 其他应付款合计 | 1,128,877.04 | 2,691,400.12 | 2,065,917.49 | 2,237,074.29 |
| 其中:应付利息 | - | - | - | 0 |
| 应付股利 | - | - | - | 0 |
| 应付分保账款 | - | - | - | 0 |
| 保险合同准备金 | - | - | - | 0 |
| 代理买卖证券款 | - | - | - | 0 |
| 代理承销证券款 | - | - | - | 0 |
| 一年内到期的非流动负债 | - | - | - | 0 |
| 其他流动负债 | 906,410.42 | 994,881.92 | 1,050,448.12 | 961,257.91 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 71,890,086.67 | 67,511,298.26 | 57,826,672.52 | 66,935,729.77 |
| 非流动负债: | | | | |
| 长期借款 | - | - | - | 0 |
| 应付债券 | - | - | - | 0 |
| 优先股 | - | - | - | 0 |
| 永续债 | - | - | - | 0 |
| 租赁负债 | - | - | - | 0 |
| 长期应付款 | - | - | - | 0 |
| 长期应付职工薪酬 | - | - | - | 0 |
| 预计负债 | - | - | - | 0 |
| 递延收益 | 7,876,516.23 | 8,119,690.91 | 8,361,856.99 | 6,546,835.52 |
| 递延所得税负债 | 11,603,037.24 | 9,804,503.28 | 8,914,623.95 | 7,097,065.15 |
| 其他非流动负债 | - | - | - | 0 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 19,479,553.47 | 17,924,194.19 | 17,276,480.94 | 13,643,900.67 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 91,369,640.14 | 85,435,492.45 | 75,103,153.46 | 80,579,630.44 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 66,666,667 | 66,666,667 | 66,666,667 | 66,666,667 |
| 其他权益工具 | - | - | - | 0 |
| 优先股 | - | - | - | 0 |
| 永续债 | - | - | - | 0 |
| 资本公积 | 1,037,419,668.53 | 1,037,419,668.53 | 1,037,419,668.53 | 1,037,419,668.53 |
| 减:库存股 | - | - | - | 0 |
| 其他综合收益 | - | - | - | 0 |
| 专项储备 | - | - | - | 0 |
| 盈余公积 | 33,073,818.61 | 33,073,818.61 | 33,073,818.61 | 33,073,818.61 |
| 一般风险准备 | - | - | - | 0 |
| 未分配利润 | 371,313,750.68 | 348,549,227.04 | 356,536,688.71 | 326,849,604.45 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,508,473,904.82 | 1,485,709,381.18 | 1,493,696,842.85 | 1,464,009,758.59 |
| 少数股东权益 | - | - | - | 0 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,508,473,904.82 | 1,485,709,381.18 | 1,493,696,842.85 | 1,464,009,758.59 |
| 负债和股东权益合计 | 1,599,843,544.96 | 1,571,144,873.63 | 1,568,799,996.31 | 1,544,589,389.03 |
| 公告日期 | 2024-10-25 | 2024-08-23 | 2024-04-20 | 2024-04-20 |
| 审计意见(境内) | | | | 标准无保留意见 |